Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramacciotti, Eduardo, Aguiar, Valéria Cristina Resende, Júnior, Valter Castelli, Casella, Ivan Benaducce, Zerati, Antonio Eduardo, Fareed, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/
https://www.ncbi.nlm.nih.gov/pubmed/30486661
http://dx.doi.org/10.1177/1076029618812955
_version_ 1783447131329134592
author Ramacciotti, Eduardo
Aguiar, Valéria Cristina Resende
Júnior, Valter Castelli
Casella, Ivan Benaducce
Zerati, Antonio Eduardo
Fareed, Jawed
author_facet Ramacciotti, Eduardo
Aguiar, Valéria Cristina Resende
Júnior, Valter Castelli
Casella, Ivan Benaducce
Zerati, Antonio Eduardo
Fareed, Jawed
author_sort Ramacciotti, Eduardo
collection PubMed
description Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.
format Online
Article
Text
id pubmed-6714848
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67148482019-09-04 Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide Ramacciotti, Eduardo Aguiar, Valéria Cristina Resende Júnior, Valter Castelli Casella, Ivan Benaducce Zerati, Antonio Eduardo Fareed, Jawed Clin Appl Thromb Hemost Original Articles Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE. SAGE Publications 2018-11-28 2018-12 /pmc/articles/PMC6714848/ /pubmed/30486661 http://dx.doi.org/10.1177/1076029618812955 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Ramacciotti, Eduardo
Aguiar, Valéria Cristina Resende
Júnior, Valter Castelli
Casella, Ivan Benaducce
Zerati, Antonio Eduardo
Fareed, Jawed
Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title_full Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title_fullStr Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title_full_unstemmed Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title_short Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
title_sort edoxaban for venous thromboembolism treatment—the new kid on the block for latin america. a practical guide
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/
https://www.ncbi.nlm.nih.gov/pubmed/30486661
http://dx.doi.org/10.1177/1076029618812955
work_keys_str_mv AT ramacciottieduardo edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide
AT aguiarvaleriacristinaresende edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide
AT juniorvaltercastelli edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide
AT casellaivanbenaducce edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide
AT zeratiantonioeduardo edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide
AT fareedjawed edoxabanforvenousthromboembolismtreatmentthenewkidontheblockforlatinamericaapracticalguide

Ejemplares similares